AbCellera Biologics said Monday that an experimental non-hormonal pill reduced the frequency and severity of menopause hot flashes by about 83 percent [1].
The results offer a potential alternative for women who cannot or choose not to use hormone replacement therapy to manage menopause symptoms. Because hot flashes often disrupt sleep and daily functioning, a non-hormonal option could expand treatment access for millions of patients.
The Canadian company conducted the Phase II trial over a period of four weeks [1]. The treatment consists of a once-a-day pill designed to alleviate the physical distress of menopause without the use of hormones [2].
Market reaction to the data was immediate. Shares of AbCellera (NASDAQ:ABCL) surged by approximately 40 percent [3] following the announcement on Aug. 10, 2026 [4].
The company said it aims to provide a solution that improves sleep and overall quality of life for women undergoing the transition to menopause [5]. While the mid-stage trial shows significant efficacy, the drug must still undergo further testing to ensure long-term safety and effectiveness before it can be approved for public use.
AbCellera is based in Canada and continues to develop biologics for various medical needs [4]. The current focus on menopause addresses a gap in the market for non-steroidal, and non-hormonal interventions.
“An experimental non-hormonal pill reduced the frequency and severity of menopause hot flashes by about 83 percent.”
The success of a non-hormonal intervention in Phase II trials suggests a shift toward targeted biological therapies for menopause. If these results hold in Phase III, it could decouple menopause symptom management from the risks associated with hormone therapy, providing a safer profile for women with specific medical contraindications.
